Results from the survey assessing willingness to receive a COVID vaccine; Dr. Fauci shares that he is ‘cautiously optimistic’ a vaccine could arrive before year’s end; And the breaking news that remdesivir (Veklury) has gained FDA approval.
The randomized, open-label, controlled trial (Study 31/A5349) had more than 2500 participants ages 12 years and older and included 214 people with HIV.
Currently, there is no available evidence to assess the carcinogenic potential of MNP and CPNP.
Shorter regimens favored over longer course of isoniazid monotherapy for latent TB infection.
A recent systematic review identified several established as well as emerging practices utilized in the pediatric setting that were associated with overuse of medical care.
The FDA has approved pretomanid tablets (TB Alliance) in combination with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).
The FDA’s Antimicrobial Drugs Advisory Committee voted in favor of pretomanid, as part of a combination regimen with bedaquiline and linezolid, for the treatment of pulmonary extensively drug resistant, treatment intolerant, or nonresponsive multidrug resistant tuberculosis.
The CDC announced an expected 3 to 10 month shortage of Aplisol (tuberculin purified protein derivative [PPD], diluted), used as an aid in the diagnosis of tuberculosis.
Compared with standard of care tests and most clinical signs, the molecular bacterial load assay demonstrated higher sensitivity and more rapid turnaround times for monitoring tuberculosis treatment.
Positive results with respect to the presence of latent tuberculosis infection in patients with renal failure were more consistent with the use of QuantiFERON-TB Gold Plus testing compared with the use of QuantiFERON-TB Gold In-Tube testing.
